Original Article
Other versions:
- ContentsContents
- Article InfoArticle Info
- CiteCite
- MetricsMetrics
- CommentComment
- RelatedRelated
- FigsFigs
- TabsTabs
- TaxaTaxa
- RefsRefs
- CitedCited
Modulating effects of microbiota on synbiotic intervention outcomes for microbiota-derived trimethylamine, trimethylamine N-oxide and indoxyl sulfate in healthy young medical students: insights from a 12-week randomized clinical trial. Journal of Translational Medicine 23: .
DOI: 10.1186/s12967-025-07345-x
Therapeutic Potential Targeting Gut Microbiota Modulation With Emphasis on Lactobacillus spp. in Common Metabolic Disorders: A Systematic Review. Scientifica 2025: .
DOI: 10.1155/sci5/3367875
Trimethylamine-N-oxide: the microbial cue in immune-mediated disorders. Trends in Endocrinology & Metabolism : .
DOI: 10.1016/j.tem.2026.02.008
Bridging the Gut Microbiota and the Brain, Kidney, and Cardiovascular Health: The Role of Probiotics. Probiotics and Antimicrobial Proteins 18: 3388.
DOI: 10.1007/s12602-025-10680-6
Bacterial dynamics govern growth trajectories and choline-derived trimethylamine production. The Journal of Nutritional Biochemistry 155: 110371.
DOI: 10.1016/j.jnutbio.2026.110371
Adjunctive use of probiotics, prebiotics, and synbiotics in endothelial dysfunction and hypertension management: a scoping review. Nutrire 51: .
DOI: 10.1186/s41110-026-00469-0
Microbiota intestinal e doenças cardiovasculares: influências dos padrões alimentares no eixo intestino coração. Research, Society and Development 14: e177141250407.
DOI: 10.33448/rsd-v14i12.50407
Classification of intestinal inflammation driven by gut microbiota metabolites: a new paradigm for precision treatment of cardiovascular diseases. Frontiers in Microbiology 17: .
DOI: 10.3389/fmicb.2026.1783688
Gut microbiota on cardiovascular diseases-a mini review on current evidence. Frontiers in Microbiology 16: .
DOI: 10.3389/fmicb.2025.1690411
Gut microbiota-derived metabolite trimethylamine N-oxide in major adverse cardiovascular events: Mechanisms, risk assessment, and therapeutic strategies. World Journal of Cardiology 18: .
DOI: 10.4330/wjc.v18.i3.116780
Lactobacillus Is Associated With Disease in Pulmonary Arterial Hypertension: A Prospective Cohort Study. Comprehensive Physiology 16: .
DOI: 10.1002/cph4.70161
Therapeutic Modulation of the Gut Microbiome in Coronary Artery Disease: Current Evidence and Future Directions. Frontiers in Bioscience-Landmark 31: .
DOI: 10.31083/FBL45081
Probiotics for managing non-alcoholic fatty liver disease: efficacy and mechanistic insights. Journal of Diabetes & Metabolic Disorders 25: .
DOI: 10.1007/s40200-026-01861-3
Microbiota-derived metabolites and cardiovascular implications in Inflammatory Bowel Disease (IBD). Molecular Medicine 32: .
DOI: 10.1186/s10020-026-01493-6
Gut microbiota‑derived metabolites in cardiovascular disease: Focus on trimethylamine N‑oxide, short‑chain fatty acids and bile acids (Review). Molecular Medicine Reports 34: 1.
DOI: 10.3892/mmr.2026.13934
Decoding the gut microbiota-mitochondrial-inflammasome axis in cardiovascular disease. Molecular and Cellular Biochemistry 481: 1081.
DOI: 10.1007/s11010-025-05451-4
Engineered bacteria: a novel era for metabolic, cardiovascular and cerebrovascular diseases therapy. Frontiers in Cardiovascular Medicine 13: .
DOI: 10.3389/fcvm.2026.1757348
Clinical landscape of gut microbiota modulators in cardiovascular disease therapy: Current status and future perspectives. International Journal of Cardiology Cardiovascular Risk and Prevention 30: 200644.
DOI: 10.1016/j.ijcrp.2026.200644
Eficácia terapêutica de probióticos presentes na composição do kefir em ensaios clínicos recentes. Caderno Pedagógico 22: e14216.
DOI: 10.54033/cadpedv22n4-179
Gut Microbiota-Derived Trimethylamine N-Oxide and NT-proBNP in Heart Failure: A Critical Review of Diagnostic and Prognostic Value. Biomedicines 14: 287.
DOI: 10.3390/biomedicines14020287
Mechanism of actions of probiotics on type 2 diabetes: Development and complications. Biomedicine & Pharmacotherapy 191: 118421.
DOI: 10.1016/j.biopha.2025.118421
A systematic review of TMAO, microRNAs, and the oral/gut microbiomes in atherosclerosis and myocardial infarction: mechanistic insights and translational opportunities. Journal of Translational Medicine 23: .
DOI: 10.1186/s12967-025-07224-5
Targeting the gut-liver-heart axis: Role of bacterial TMA lyase and human FMO-3 in atherosclerosis and dietary interventions. Glycoscience & Therapy 2: 100029.
DOI: 10.1016/j.glycos.2026.100029
Subscribe to email alerts for current Article's categories